✕
☰

Start-ups supported with €5.5m following COVID-19 disruptions

EIT Health has awarded €5.5 million to start-ups in Europe to support with business continuity in response to the disruptions caused by the COVID-19 pandemic.

The Start-up Rescue Instrument was initiated by EIT Health in May and called on biotech, medtech and digital health start-ups to apply to receive up to €500,000 in co-investment from EIT Health, in return for options. The instrument was launched to alleviate the financial shock posed by COVID-19 and bridge the fundraising gap of start-ups in Series A, Series B and bridge-financing rounds.

In April, a report from ‘European Start-ups’, a two-year project backed by the European Commission and European Parliament, found that venture capital (VC) activity is expected to significantly slow during the pandemic, leading to cash flow concerns for start-ups. VC typically accounts for approximately 30-40% of funds raised by start-ups in Europe, which represents a significant proportion. With the report detailing that European start-ups employ two million people, the effects of failing to address the economic impact of COVID-19 on start-ups are far reaching.

Kurt Höller, director of business creation, EIT Health, said: “In the current climate, many start-ups are experiencing issues in raising funding rounds that are critical to their future. We have extremely promising start-ups here in Europe, and we cannot sit by and allow the existence of a generation of emerging companies to be threatened by COVID-19. We are doing everything within our power to support start-ups during this difficult economic time. However, it is not all doom and gloom – health has never been so front of mind, and start-ups with the ability to be agile within the changing environment can find themselves on the precipice of a whole new wave of opportunity.”

Despite the warning signs, health-related start-ups are expected to be one of the least affected sectors by COVID-19, with the report from ‘European Start-ups’ outlining telemedicine as experiencing a 54% growth in share prices since January. Telemedicine is followed by pet care (52%), pharmacy (30%), and groceries (21%). 

The eleven start-ups selected will receive up to €500,000, and are developing solutions in cancer, infectious diseases, wound and joint care, medical imaging, and cardiovascular disease.

The selected start-ups are:

Back to topbutton